Table 1 Baseline features at presentation and therapy in 52 patients with antineutrophil cytoplasmic antibodies-associated vasculitis

Diagnosis

   Granulomatosis with polyangiitis

33 (63.5)

   Microscopic polyangiitis

11 (21.2)

   Renal limited vasculitis

8 (15.4)

ANCA

   Proteinase 3 ANCA

30 (57.7)

   Myeloperoxidase ANCA

22 (42.3)

Disease activity

   Median BVAS

15.0 (12.0 to 23.5)

   Median C-reactive protein level (mg/l)

37.0 (11.5 to 81.5)

Disease manifestations

   Renal involvement

39 (75.0)

   Systemic manifestations

32 (61.5)

   Ear, nose and throat involvement

28 (53.8)

   Pulmonary involvement

22 (42.3)

   Arthritis/joint pain

18 (34.6)

   Peripheral neuropathy

15 (28.8)

   Eye involvement

13 (25.0)

   Cutaneous vasculitis

12 (23.1)

Pulmonary involvement

   Pulmonary nodules and/or infiltrates

12 (23.0)

   Alveolar hemorrhage

6 (11.5)

   Pleural effusion

2 (3.8)

   Endobronchial lesion

1 (1.9)

Renal-related variables

   Median 24-hour proteinuria (g)

0.90 (0.55 to 1.60)

   Hematuria (>10 RBC/HPF)

39 (75.0)

   Median creatinine (μmol/l)

137.0 (80.0 to 350.0)

   Mean creatinine clearance (ml/minute/1.73 m²)

65.7 ± 41.7

   Dialysis dependent

8 (15.4)

Actual therapy

   Patients without treatment

27 (51.9)

   Prednisolone and cyclophosphamide

13 (25.0)

   Prednisolone only

7 (13.5)

   Plasmapheresis

6 (11.5)

   Mean number of plasmapheresis sessions

9.33 ± 1.50

   Methotrexate

1 (1.9)